Opinion|Videos|November 15, 2024
Long-Term Outcomes of BRAF-MEK Inhibitor Combinations
Panelists discuss recent data on progression-free survival (PFS) and duration of response (DOR) for BRAF-MEK inhibitor combinations, including encorafenib + binimetinib and dabrafenib + trametinib, while also addressing emerging safety signals, differences in response based on treatment lines, and considerations for dose modifications and sequencing strategies in clinical practice.
Advertisement
- All: Please discuss the recent data on PFS and DOR for BRAF-MEK inhibitors combinations.
- Encorafenib + binimetinib (
Riely GJ, et al. J Clin Oncol. 2023 ) - Dabrafenib + trametinib (
Planchard D, et al. J Thorac Oncol. 2022 )
- Encorafenib + binimetinib (
- Have any new safety signals emerged from long-term follow-up?
- Encorafenib + binimetinib (
Smit E, et al. 2024.WCLC. MA06.13 - Encorafenib + binimetinib (
Riely G, et al. 2024.ESMO.LBA56 )- Impression of overall survival data
- Impact on clinical practice
- Difference in responses in first line vs second line
- Encorafenib + binimetinib (
- How do you choose between different BRAF-MEK inhibitor
- Based on the recent data presented at ESMO, how do you approach dose modifications?
- First-line immunotherapy vs BRAF and MEK inhibitors (
Di Federico A, et al. 2024. ESMO. Abstract 1299p ) - Treatment sequences in BRAF-V600 mutant (
Wiesweg M, et al. 2024. ESMO Abstract 1300p
Advertisement
Latest CME
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma
2
PD-L1 Expression Is More Predictive of Response to Pembrolizumab on Metastatic Sites in High-Grade Serous Ovarian Cancer
3
Lurbinectedin-Based Triplet Shows Clinical Benefit in Advanced Soft Tissue Sarcoma
4
Dr Braunstein on the FDA Approval of Subcutaneous Daratumumab With VRd For Newly Diagnosed Multiple Myeloma
5































